Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Clinical Trial Updates, Appointments, FDA Acknowledgments and Qualifications - Research Report on Novartis, Endo, The Medicines



Clinical Trial Updates, Appointments, FDA Acknowledgments and Qualifications -
Research Report on Novartis, Endo, The Medicines Company, United Therapeutics,
                                  and Forest

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 17, 2013

NEW YORK, September 17, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Novartis
AG (NYSE: NVS), Endo Health Solutions Inc. (NASDAQ: ENDP), The Medicines
Company (NASDAQ: MDCO), United Therapeutics Corporation (NASDAQ: UTHR), and
Forest Laboratories, Inc. (NYSE: FRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Novartis AG Research Report

On September 8, 2013, Novartis AG (Novartis) announced new analyses of data
for once-daily Ultibro Breezhaler (investigational QVA149), which showed
significant improvements in lung function, shortness of breath, and
health-related quality of life for chronic obstructive pulmonary disease
(COPD) patients, versus all comparators. "Novartis is pleased that these new
analyses further support that the efficacy of dual therapy, which has the
potential to make a real difference to peoples' lives," said Tim Wright, Head
of Development at Novartis Pharmaceuticals. According to Novartis,
investigational QVA149 is currently being assessed in a clinical trial program
involving over 10,000 patients, and in July 2013, it received a positive
opinion for approval from the European Medicine Agency's (EMA) Committee for
the Human use of Medicinal Products (CHMP) as a maintenance bronchodilator
treatment to relieve symptoms in adult patients with COPD. The Full Research
Report on Novartis AG - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-12/NVS]

--

Endo Health Solutions Inc. Research Report

On September 9, 2013, Endo Health Solutions Inc. (Endo) announced the
appointment of Suketu Upadhyay as the Company's Executive Vice President and
CFO, effective September 23, 2013. Prior to joining Endo, Upadhyay served at
Becton, Dickinson & Company's (BD) as the Principal Accounting Officer and
interim CFO. Rajiv De Silva, President and CEO of Endo said, "He brings
significant healthcare industry experience and a track record of delivering
value that will be instrumental in the execution of our new growth strategy.
His breadth of experience will be an asset to the company as we chart our
course forward." The Full Research Report on Endo Health Solutions Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-12/ENDP]

--

The Medicines Company Research Report

On September 10, 2013, The Medicines Company announced the results for its
Phase 3 SOLO clinical trial program of oritavancin, which is currently under
investigation for the treatment of acute bacterial skin and skin structure
infections (ABSSSI) caused by susceptible gram-positive bacteria. Ralph Corey
MD, Professor of Medicine and Infectious Disease at Duke University and
Principal Investigator of the SOLO trials said, "What is unique about this
study is it is testing an antibiotic where the full course of treatment has
been given to the patient through one administration. This study shows that a
single 1200 mg dose of oritavancin was non inferior to 7 to 10 days of
vancomycin in treating ABSSSI caused by gram-positive pathogens including
methicillin-resistant Staphylococcus aureus, MRSA." The Company informed that
all protocol-specified primary and secondary efficacy endpoints were met in
both SOLO I and SOLO II trials. The Full Research Report on The Medicines
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-12/MDCO]

--

United Therapeutics Corporation Research Report

On September 11, 2013, United Therapeutics Corporation (United Therapeutics)
announced that the FDA has acknowledged its resubmission of the NDA for
treprostinil diolamine extended release tablets (oral treprostinil) for the
treatment of pulmonary arterial hypertension. The Company informed that the
FDA has classified the NDA resubmission as a complete, class 2 response to its
March 22, 2013 complete response letter, and has set a user fee goal date of
February 16, 2014. The Full Research Report on United Therapeutics Corporation
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-12/UTHR]

--

Forest Laboratories, Inc. Research Report

On September 12, 2013, Forest Laboratories, Inc. (Forest) announced that the
FDA has designated its investigational drug, ceftazidime/avibactam, as a
qualified infectious disease product (QIDP). The Company informed that
ceftazidime/avibactam is currently in Phase III trials to investigate efficacy
in treating hospitalized patients with complicated intra-abdominal infections
(cIAI) and complicated urinary tract infections (cUTI). The investigational
drug has received QIDP designation for complicated intra-abdominal infections
(cIAI), complicated urinary tract infections (cUTI) and hospital-acquired
bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP). The
Full Research Report on Forest Laboratories, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-12/FRX]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: CONTACT PERSON: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement